Should I buy or sell IGM Biosciences stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IGM Biosciences in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IGMS shares. View IGMS analyst ratings or view top-rated stocks .

What is IGM Biosciences' stock price target for 2024?

8 analysts have issued 1 year target prices for IGM Biosciences' stock. Their IGMS share price targets range from $8.00 to $25.00. On average, they predict the company's stock price to reach $17.44 in the next twelve months. This suggests a possible upside of 142.3% from the stock's current price. View analysts price targets for IGMS or view top-rated stocks among Wall Street analysts .

How have IGMS shares performed in 2024?

IGM Biosciences' stock was trading at $8.31 at the beginning of 2024. Since then, IGMS stock has decreased by 13.4% and is now trading at $7.20. View the best growth stocks for 2024 here .

Are investors shorting IGM Biosciences?

IGM Biosciences saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 5,220,000 shares, an increase of 9.7% from the March 15th total of 4,760,000 shares. Based on an average daily trading volume, of 281,700 shares, the short-interest ratio is presently 18.5 days. Currently, 25.1% of the company's shares are sold short. View IGM Biosciences' Short Interest .

When is IGM Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our IGMS earnings forecast .

How were IGM Biosciences' earnings last quarter?

IGM Biosciences, Inc. (NASDAQ:IGMS) announced its earnings results on Thursday, March, 7th. The company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.05. The firm earned $0.65 million during the quarter, compared to the consensus estimate of $0.95 million. IGM Biosciences had a negative net margin of 11,568.83% and a negative trailing twelve-month return on equity of 103.20%.

What ETFs hold IGM Biosciences' stock?

ETFs with the largest weight of IGM Biosciences (NASDAQ:IGMS) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Loncar China Biopharma ETF (CHNA) . Virtus LifeSci Biotech Clinical Trials ETF (BBC) .

What other stocks do shareholders of IGM Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IGM Biosciences investors own include Pfizer (PFE) , Tesla (TSLA) , AbbVie (ABBV) , ImmunoGen (IMGN) , Plug Power (PLUG) , Atreca (BCEL) , Carnival Co. & (CCL) , Cisco Systems (CSCO) , Dropbox (DBX) and Energy Transfer (ET) .

When did IGM Biosciences IPO?

IGM Biosciences (IGMS) raised $125 million in an initial public offering (IPO) on Wednesday, September 18th 2019. The company issued 7,800,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

How do I buy shares of IGM Biosciences?

Shares of IGMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:IGMS

IGM Biosciences (IGMS) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free IGMS Stock Alerts

$7.20

-0.21 (-2.83%)

(As of 04/19/2024 ET)

Compare

Today's Range: $7.04
▼
$7.43
50-Day Range: $7.20
▼
$17.36
52-Week Range: $3.81
▼
$17.70

Volume: 219,365 shs
Average Volume: 223,157 shs
Market Capitalization: $423.29 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.44

Get IGM Biosciences alerts:

IGM Biosciences MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 142.3% Upside
$17.44 Price Target
Short Interest: Bearish
25.10% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.08
Upright™ Environmental Score
News Sentiment: 0.40
Based on 14 Articles This Week
Insider Trading: Acquiring Shares
$3.17 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($3.23) to ($3.03) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.88 out of 5 stars

Medical Sector

216th out of 911 stocks

Pharmaceutical Preparations Industry

85th out of 419 stocks

3.3

Analyst's Opinion

Consensus Rating
IGM Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.
Amount of Analyst Coverage
IGM Biosciences has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
25.10% of the float of IGM Biosciences has been sold short.
Short Interest Ratio / Days to Cover
IGM Biosciences has a short interest ratio ("days to cover") of 18.5, which indicates bearish sentiment.
Change versus previous month
Short interest in IGM Biosciences has recently increased by 9.66%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
IGM Biosciences does not currently pay a dividend.
Dividend Growth
IGM Biosciences does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
IGM Biosciences has received a 71.95% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Clinical research services for infectious diseases" products. See details.
Environmental Sustainability
The Environmental Impact score for IGM Biosciences is -1.08.

2.4

News and Social Media Coverage

News Sentiment
IGM Biosciences has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 14 news articles for IGM Biosciences this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for IGMS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
2 people have added IGM Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IGM Biosciences insiders have bought 3,814.50% more of their company's stock than they have sold. Specifically, they have bought $3,167,890.00 in company stock and sold $80,927.00 in company stock.
Percentage Held by Insiders
56.91% of the stock of IGM Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
42.79% of the stock of IGM Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for IGM Biosciences are expected to grow in the coming year, from ($3.23) to ($3.03) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of IGM Biosciences is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of IGM Biosciences is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
IGM Biosciences has a P/B Ratio of 2.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About IGM Biosciences Stock (NASDAQ:IGMS)

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

IGMS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IGMS Stock News Headlines

March 29, 2024 | insidertrades.com

IGM Biosciences, Inc. (NASDAQ:IGMS) Director Acquires $937,690.26 in Stock

April 20, 2024 | americanbankingnews.com

HC Wainwright Reiterates "Neutral" Rating for IGM Biosciences (NASDAQ:IGMS)

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 19, 2024 | finance.yahoo.com

IGM Biosciences Insiders Placed Bullish Bets Worth US$992.2k

April 18, 2024 | markets.businessinsider.com

What 5 Analyst Ratings Have To Say About IGM Biosciences

April 18, 2024 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: IGM Biosciences (IGMS) and Argenx Se (ARGX)

April 17, 2024 | bizjournals.com

Big drugmaker's cancer rollback trickles down to another Bay Area company

April 17, 2024 | finanznachrichten.de

IGM Biosciences, Inc.: IGM Biosciences Announces Refocusing of Sanofi Collaboration

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 17, 2024 | markets.businessinsider.com

Why IGM Biosciences Is Rising In Pre-market?

April 17, 2024 | finance.yahoo.com

IGM Biosciences Announces Refocusing of Sanofi Collaboration

April 17, 2024 | globenewswire.com

IGM Biosciences Announces Refocusing of Sanofi Collaboration

April 14, 2024 | americanbankingnews.com

IGM Biosciences (NASDAQ:IGMS) Trading Up 2.4%

April 10, 2024 | globenewswire.com

IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum

April 8, 2024 | finance.yahoo.com

IGM Biosciences, Inc. (IGMS)

March 19, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Alpine Immune Sciences (ALPN) and IGM Biosciences (IGMS)

March 15, 2024 | finance.yahoo.com

IGMS Apr 2024 22.500 call

March 9, 2024 | finance.yahoo.com

IGM Biosciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

March 9, 2024 | finanznachrichten.de

IGM Biosciences, Inc.: IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

March 8, 2024 | investorplace.com

IGMS Stock Earnings: IGM Biosciences Beats EPS, Misses Revenue for Q4 2023

March 7, 2024 | stockhouse.com

IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

March 7, 2024 | msn.com

IGM Biosciences GAAP EPS of -$1.01 beats by $0.08, revenue of $0.7M misses by $0.07M

March 7, 2024 | globenewswire.com

IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

February 24, 2024 | msn.com

IGM Biosciences (IGMS) Price Target Increased by 9.28% to 21.01

February 22, 2024 | benzinga.com

IGM Biosciences Stock (NASDAQ:IGMS), Short Interest Report

February 14, 2024 | finance.yahoo.com

Wall Street Analysts Believe IGM Biosciences, Inc. (IGMS) Could Rally 35.08%: Here's is How to Trade

February 12, 2024 | seekingalpha.com

IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points

See More Headlines

Receive IGMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IGM Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/07/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:IGMS
CUSIP: N/A
CIK: 1496323
Web: igmbio.com
Phone: 650-965-7873
Fax: N/A
Employees: 224
Year Founded: 2010

Price Target and Rating

Average Stock Price Target: $17.44
High Stock Price Target: $25.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +142.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.81)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-246,420,000.00
Net Margins: -11,568.83%
Pretax Margin: -11,537.00%
Return on Equity: -103.20%
Return on Assets: -53.53%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.18
Quick Ratio: 8.18

Sales & Book Value

Annual Sales: $2.13 million
Price / Sales: 198.73
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.46 per share
Price / Book: 2.08

Miscellaneous

Outstanding Shares: 58,790,000
Free Float: 25,331,000
Market Cap: $423.29 million
Optionable: Optionable
Beta: 0.26

Social Links

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Fred M. Schwarzer J.D. (Age 71)
CEO, President & Director
Comp: $977.66k
Dr. Bruce A. Keyt Ph.D. (Age 70)
Chief Scientific Officer
Comp: $692.95k
Dr. Chris H. Takimoto FACP (Age 65)
M.D., Ph.D., Chief Medical Officer
Comp: $684.95k
Mr. Misbah Tahir (Age 48)
Chief Financial Officer
Comp: $957.6k
Mr. TS Harigopal
Senior Vice President of Group Operations
Mr. Steven Weber (Age 48)
Senior VP, Corporate Controller & Principal Accounting Officer
Mr. Paul C. Graffagnino
Senior Vice President of Legal Affairs
Ms. Suzette Tauber (Age 60)
Chief Human Resources Officer
Dr. Angus M. Sinclair Ph.D.
Senior Vice President of Immuno-Oncology
Dr. Lisa L. Decker Ph.D. (Age 54)
Chief Business Officer
Comp: $528.18k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IGMS Stock Analysis - Frequently Asked Questions

Should I buy or sell IGM Biosciences stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IGM Biosciences in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IGMS shares.
View IGMS analyst ratings or view top-rated stocks.
What is IGM Biosciences' stock price target for 2024?: 8 analysts have issued 1 year target prices for IGM Biosciences' stock. Their IGMS share price targets range from $8.00 to $25.00. On average, they predict the company's stock price to reach $17.44 in the next twelve months. This suggests a possible upside of 142.3% from the stock's current price.
View analysts price targets for IGMS or view top-rated stocks among Wall Street analysts.
How have IGMS shares performed in 2024?: IGM Biosciences' stock was trading at $8.31 at the beginning of 2024. Since then, IGMS stock has decreased by 13.4% and is now trading at $7.20.
View the best growth stocks for 2024 here.
Are investors shorting IGM Biosciences?: IGM Biosciences saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 5,220,000 shares, an increase of 9.7% from the March 15th total of 4,760,000 shares. Based on an average daily trading volume, of 281,700 shares, the short-interest ratio is presently 18.5 days. Currently, 25.1% of the company's shares are sold short.
View IGM Biosciences' Short Interest.
When is IGM Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our IGMS earnings forecast.
How were IGM Biosciences' earnings last quarter?: IGM Biosciences, Inc. (NASDAQ:IGMS) announced its earnings results on Thursday, March, 7th. The company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.05. The firm earned $0.65 million during the quarter, compared to the consensus estimate of $0.95 million. IGM Biosciences had a negative net margin of 11,568.83% and a negative trailing twelve-month return on equity of 103.20%.

What ETFs hold IGM Biosciences' stock?: ETFs with the largest weight of IGM Biosciences (NASDAQ:IGMS) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Loncar China Biopharma ETF (CHNA).Virtus LifeSci Biotech Clinical Trials ETF (BBC).
What other stocks do shareholders of IGM Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other IGM Biosciences investors own include Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), ImmunoGen (IMGN), Plug Power (PLUG), Atreca (BCEL), Carnival Co. & (CCL), Cisco Systems (CSCO), Dropbox (DBX) and Energy Transfer (ET).
When did IGM Biosciences IPO?: IGM Biosciences (IGMS) raised $125 million in an initial public offering (IPO) on Wednesday, September 18th 2019. The company issued 7,800,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, Stifel and Guggenheim Securities acted as the underwriters for the IPO.
How do I buy shares of IGM Biosciences?: Shares of IGMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IGMS) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

IGM Biosciences (IGMS) Stock Price, News & Analysis

IGM Biosciences MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About IGM Biosciences Stock (NASDAQ:IGMS)

IGMS Stock Price History

IGMS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

IGMS Stock Analysis - Frequently Asked Questions

Overall MarketRank^™